Crossmark

Percutaneous versus thoracoscopic ablation of symptomatic paroxysmal atrial fibrillation: a randomised controlled trial - the FAST II study

Crossref DOI link: https://doi.org/10.1186/s13019-018-0792-8

Published Online: 2018-10-03

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sindby, Jesper Eske http://orcid.org/0000-0001-6114-4882
Vadmann, Henrik

Lundbye-Christensen, Søren

Riahi, Sam

Hjortshøj, Søren

Boersma, Lucas V A

Andreasen, Jan Jesper
Funding

Funding for this research was provided by:

Strategiske Forskningsråd
License Information

Text and Data Mining valid from 2018-10-03
More Information

Article History

Received: 22 June 2018

Accepted: 25 September 2018

First Online: 3 October 2018

Ethics approval and consent to participate

: The Danish Ethics Committee approved the study (VEK project ID: N20110009), and the trial was registered at ClinicalTrials.gov - Identifier: NCT01336075.

: Not applicable.

: L.Boersma have received grants from Medtronic, Boston Scientific and Abbott as a consultant.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.